Revascularization Strategies for STEMI; The CMR Endpoint Study

Revascularization Strategies for ST Elevation Myocardial Infarction; The Cardiac Magnetic Resonance Endpoint Study

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01818960

Acronym

ASSIST-CMR

Enrollment

250

Registered

2013-03-27

Start date

2014-04-30

Completion date

2018-07-31

Last updated

2016-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction

Keywords

Stent, Myocardial Infarction, Coronary Intervention

Brief summary

Revascularization strategies for ST elevation myocardial infarction (STEMI) study (ASSIST-CMR) will compare the effects of two revascularization strategies \[same sitting multivessel primary PCI (SS-PCI) and culprit vessel only primary PCI (IRA-PCI)\] on myocardial infarct size (MIS) as determined by cardiac magnetic resonance (CMR) imaging in patients presenting with STEMI and multivessel disease (MVD).

Interventions

PROCEDUREIRA-PCI

IRA only PCI at the time of Primary PCI

PROCEDURESS-PCI

Same sitting multivessel PCI as an adjunct to primary PCI

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* High risk ST elevation myocardial infarction evidenced by: ≥2 mm ST elevation in 2 anterior or lateral leads; or ≥2 mm ST elevation in 2 inferior coupled with ST depression in 2 contiguous anterior leads for a total ST deviation of ≥8 mm; or New left bundle branch block with at least 1 mm concordant ST elevation. * Multivessel CAD as evidenced by ≥1 significant (≥70% by visual assessment or FFR\<0.80 for 50-70% stenosis) stenosis in non-IRA. * Successful IRA-PCI with \<10% residual angiographic stenosis and TIMI III flow. * Written informed consent.

Exclusion criteria

* Age ≤ 18 years. * Prior coronary artery bypass graft (CABG) surgery. * Administration of thrombolytic therapy. * Non-IRA stenosis is a chronic total occlusion or located in left main artery. * Hemodynamic instability evidenced by BP\<90 mmHg, Killip class ≥2, need for inotropes/vasopressors. * Known renal insufficiency (estimated GFR \< 50ml/min). * Contraindication to CMR.

Design outcomes

Primary

Measure	Time frame
Infarct size by CMR	90 days

Secondary

Measure	Time frame	Description
MACE rate	One year	MACE rate at 12 months

Other

Measure	Time frame
LV function	90 days and one year

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026